Changes in Cardiovascular Disease Risk, Lung Function, and Other Clinical Health Outcomes When People Who Smoke Use E-cigarettes to Reduce Cigarette Smoking: An Exploratory Analysis from a Randomized Placebo-Controlled Trial

Introduction The health effects of dual use of electronic cigarettes (e-cigarettes) and combustible cigarettes are unclear. We report on differences in cardiovascular disease (CVD) risk factors, lung function, and clinical laboratory markers among people who smoke used e-cigarettes to reduce their cigarette smoking in a randomized placebo-controlled trial.

Methods Participants (n=520) who regularly smoked cigarettes were randomized to 1 of 4 conditions (e-cigarette device paired with liquid containing 0, 8, or 36 mg/mL of nicotine or a cigarette-substitute [CS]) and encouraged to reduce their smoking over 6 months. Group differences were assessed between the e-cigarettes and CS conditions at baseline and 6-month using one-way ANOVA and linear mixed-effects model. Multi-testing adjustment was not applied as the analysis was exploratory in nature. Primary outcomes were: CVD risk (i.e., blood lipids, C-reactive protein, blood pressure, heart rate, waist-to-hip ratio, body mass index, and INTERHEART risk score), lung function (i.e., spirometry indices and clinical COPD questionnaire), and other clinical laboratory markers (i.e., complete blood count and complete metabolic panel).

Results At 6-month, use of nicotine e-cigarettes caused no significant differences from control groups for most measures. However, participants randomized to 36 mg/mL e-cigarettes had significantly higher levels of high-density lipoprotein (HDL) (p=0.003 in unadjusted analysis, p=0.002 in adjusted analysis), and lower levels of low-density lipoprotein (LDL) (p=0.044 in adjusted analysis) and cholesterol/HDL ratio (p=0.034 in unadjusted analysis, p=0.026 in adjusted analysis) as compared to CS. Also, those in the 36 mg/mL e-cigarette condition had higher levels of HDL as compared to those in 0 mg/mL condition (p=0.016 in unadjusted analysis, p=0.019 in adjusted analysis).

Conclusions Those randomized to the highest nicotine e-cigarettes had small improvement in some measures of blood lipids (e.g., increased HDL, and reduced LDL and cholesterol/HDL ratio) as compared to a non-aerosol CS among individuals attempting to reduce their cigarette smoking. Future studies of e-cigarettes for smoking cessation would benefit from including these measures to further explore the results found in this study.

Trial Registration ClinicalTrials.gov, NCT02342795.

Strengths and limitations of this study

• The use of a randomized double-blind placebo-controlled trial design with two nicotine concentrations and a relatively long follow-up period (6 months).

• Use of an additional randomized control group who did not use an electronic cigarette device, but were given a “cigarette substitute” product with no aerosol but similar behavioral requirements.

• Participants had to be daily cigarette smokers with no plans to quit smoking, but an interest in reducing, and were recruited from two U.S. sites. The results may only be generalizable to similar populations.

• These were exploratory analyses of a comprehensive group of commonly used clinical markers, rather than hypothesis-driven primary outcomes. These results therefore provide a preliminary assessment of effects that may inform future studies.